Edition:
United Kingdom

Bellicum Pharmaceuticals Inc (BLCM.OQ)

BLCM.OQ on NASDAQ Stock Exchange Global Market

3.80USD
3:21pm GMT
Change (% chg)

$-0.01 (-0.26%)
Prev Close
$3.81
Open
$3.86
Day's High
$3.90
Day's Low
$3.72
Volume
19,665
Avg. Vol
99,723
52-wk High
$10.23
52-wk Low
$3.45

Latest Key Developments (Source: Significant Developments)

Bellicum Reports Safety Results For Pancreatic Cancer Drug
Friday, 14 Dec 2018 

Dec 14 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM REPORTS SAFETY RESULTS AND PROMISING ACTIVITY OF ITS CONTROLLED CAR-T CANDIDATE BPX-601 IN PATIENTS WITH ADVANCED PANCREATIC CANCER AT ESMO-IO.BELLICUM PHARMACEUTICALS INC - BPX-601 WAS WELL-TOLERATED WITH NO CRS OR NEUROTOXICITY REPORTED IN INITIAL CELL-DOSE ESCALATION.BELLICUM PHARMACEUTICALS INC - INITIAL EVIDENCE OF BIOLOGIC ACTIVITY AND STABLE DISEASE OBSERVED IN SOME PATIENTS WITH SINGLE RIMIDUCID DOSE.BELLICUM PHARMACEUTICALS INC - RIMIDUCID-ACTIVATED GOCAR-T(®) RESULTED IN SIGNIFICANT EXPANSION AND PERSISTENCE OF T CELLS.BELLICUM PHARMACEUTICALS INC - TO ADD ADDITIONAL TUMOR TYPES IN PART 2 OF STUDY, INCORPORATING STANDARD LYMPHODEPLETION AND REPEAT RIMIDUCID DOSING.BELLICUM PHARMACEUTICALS INC - LOOK FORWARD TO REPORTING UPDATED RESULTS OF BPX-601 STUDY IN 2019.  Full Article

Bellicum Pharmaceuticals Appoints Atabak Mokari As CFO
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM PHARMACEUTICALS APPOINTS ATABAK MOKARI AS CHIEF FINANCIAL OFFICER.BELLICUM PHARMACEUTICALS INC - APPOINTMENT OF ATABAK MOKARI AS CHIEF FINANCIAL OFFICER, EFFECTIVE DECEMBER 19.BELLICUM PHARMACEUTICALS INC - MOKARI JOINS BELLICUM FROM IRIDEX CORPORATION.  Full Article

Bellicum Pharma Files For Mixed Shelf Of Upto $150 Million
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.  Full Article

Bellicum Pharmaceuticals Says On July 13, Co, CFO, Alan Musso Entered Separation Agreement After Which Musso Resigned Effective Aug 31
Monday, 16 Jul 2018 

July 16 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM PHARMACEUTICALS SAYS ON JULY 13, CO, CFO, ALAN MUSSO ENTERED SEPARATION AGREEMENT AFTER WHICH MUSSO RESIGNED EFFECTIVE AUGUST 31 - SEC FILING.  Full Article

Bellicum Announces Clinical Hold Lifted On U.S. Studies Of BPX-501
Wednesday, 11 Apr 2018 

April 11 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM ANNOUNCES CLINICAL HOLD LIFTED ON U.S. STUDIES OF BPX-501.FDA CLINICAL HOLD DID NOT AFFECT BP-004 REGISTRATIONAL TRIAL IN EUROPE, WHICH IS FULLY ENROLLED.LIFT OF CLINICAL HOLD FOLLOWS CONSULTATION WITH FDA & AGREEMENT ON AMENDMENTS TO STUDY PROTOCOLS.BELLICUM WILL BE WORKING WITH U.S. CLINICAL SITES TO RESUME PATIENT RECRUITMENT BASED ON AMENDED PROTOCOLS.  Full Article

Bellicum reports qtrly earnings per share loss‍ $0.71​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Bellicum Pharmaceuticals Inc ::Bellicum reports third quarter 2017 financial results.Bellicum Pharmaceuticals Inc qtrly earnings per share loss‍ $0.71​.Q3 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S.  Full Article

Bellicum announces appointment of Rick Fair as CEO
Tuesday, 31 Jan 2017 

Bellicum Pharmaceuticals Inc : Bellicum announces appointment of Rick Fair as chief executive officer in preparation for commercialization of bpx-501 and next phase of growth . Bellicum pharmaceuticals - fair joins Bellicum from Genentech/Roche, where he was senior vice president, head of oncology global product strategy .Bellicum Pharmaceuticals Inc - Fair succeeds Tom Farrell, who will serve as an advisor to company during transition.  Full Article